ライフサイエンスコーパス: nicotinic acid

1 rs a (SCS)Ni(II) pincer complex derived from nicotinic acid.

2 at T41 and F124 affect the interactions with nicotinic acid.

3 er assayed for PGD(2) release in response to nicotinic acid.

4 able to release PGD(2) upon stimulation with nicotinic acid.

5 nd the characteristic side-effect profile of nicotinic acid.

6 (NAAD) as a cosubstrate and is inhibited by nicotinic acid.

7 een regression of atherosclerosis and use of nicotinic acid.

8 nc1 is a nicotinamidase that converts NAM to nicotinic acid.

9 -the-counter niacin that do not contain free nicotinic acid.

10 s that led to increased NAMN production from nicotinic acid.

11 known to be auxotrophic for nicotinamide or nicotinic acid.

12 salvage enzymes that convert nicotinamide to nicotinic acid.

13 unmodified polar isosteres of pyrazinoic and nicotinic acids.

14 unmodified polar isosteres of pyrazinoic and nicotinic acids.

15 le the hepatic glucose load), and peripheral nicotinic acid (1.5 mg.kg(-1).min(-1)) were infused.

16 repared by reacting 2-trifluoromethyl-4-iodo-nicotinic acid (2) with amidine 9a catalyzed by Pd(2)(db

17 2,4-dioxo-1,3,7-tria zaspiro-[4.4]nonan-7-yl)nicotinic acid (2e) was selected to advance into clinica

18 onicotinic acid was discovered to afford the nicotinic acid 3.

19 omly assigned to receive niacin (crystalline nicotinic acid), 3000 mg/d or maximum tolerated dosage (

20 unctionalized substituents introduced at the nicotinic acid 5-position are recognized by the sea urch

21 The two most potent compounds [compound 1, nicotinic acid [5-(3-bromophenyl)-2-furyl]methylene-hydr

22 , some amino acids, thymidine, trigonelline, nicotinic acid, 5,6-dihydrouracil, hesanal, cis-olefin,

23 Similarly, treatment with nicotinic acid, a lipolysis inhibitor, restored insulin-

24 mophila differentiation is also triggered by nicotinic acid, a precursor of the central metabolite NA

25 se domain to supply ammonia for amidation of nicotinic acid adenine dinucleotide (NaAD(+)) to NAD(+).

26 hat LarB carboxylates the pyridinium ring of nicotinic acid adenine dinucleotide (NaAD) and cleaves t

27 a mutant that deacetylates peptides by using nicotinic acid adenine dinucleotide (NAAD) as a cosubstr

28 We also report that nicotinic acid adenine dinucleotide (NAAD), which was no

29 xtracts of HeLa cells, NAADP was degraded to nicotinic acid adenine dinucleotide (NAAD).

30 metabolites by phosphorylating nicotinamide/nicotinic acid adenine dinucleotide at the adenosine 3'-

31 tinic acid and metabolize exogenous NAADP to nicotinic acid adenine dinucleotide by a 2'-phosphatase.

32 Both products of AvrRxo1, 3'-NADP and 3'-nicotinic acid adenine dinucleotide phosphate (3'-NAADP)

33 synthesized and characterized [(32)P-5-azido]nicotinic acid adenine dinucleotide phosphate ([(32)P-5N

34 duce adenosine diphosphate ribose (ADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP(+))

35 Nicotinic acid adenine dinucleotide phosphate (NAADP) an

36 -pore channel blocker NED-19 (1 mum) and the nicotinic acid adenine dinucleotide phosphate (NAADP) an

37 we identify the Ca(2+)-mobilizing messenger nicotinic acid adenine dinucleotide phosphate (NAADP) an

38 rt that although Ca(2+) increases induced by nicotinic acid adenine dinucleotide phosphate (NAADP) ar

39 ncreatic acinar nuclei could be activated by nicotinic acid adenine dinucleotide phosphate (NAADP) as

40 arterial smooth muscle cells have shown that nicotinic acid adenine dinucleotide phosphate (NAADP) ev

41 We show that IP(3), cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) ev

42 nicotinamide adenine dinucleotide (NAD) and nicotinic acid adenine dinucleotide phosphate (NAADP) fr

43 Nicotinic acid adenine dinucleotide phosphate (NAADP) ha

44 Cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP) ha

45 +)](i) via the novel Ca(2+)-mobilizing agent nicotinic acid adenine dinucleotide phosphate (NAADP) in

46 We show here that intracellular dialysis of nicotinic acid adenine dinucleotide phosphate (NAADP) in

47 We investigated the effect of nicotinic acid adenine dinucleotide phosphate (NAADP) in

48 ch to detecting the calcium second messenger nicotinic acid adenine dinucleotide phosphate (NAADP) in

49 Accumulating evidence implicates nicotinic acid adenine dinucleotide phosphate (NAADP) in

50 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

51 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

52 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

53 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

54 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

55 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

56 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

57 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

58 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

59 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

60 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

61 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

62 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

63 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

64 Nicotinic acid adenine dinucleotide phosphate (NAADP) is

65 izing messengers described, the most potent, nicotinic acid adenine dinucleotide phosphate (NAADP) is

66 The measurement of changes in nicotinic acid adenine dinucleotide phosphate (NAADP) le

67 Nicotinic acid adenine dinucleotide phosphate (NAADP) mo

68 el intracellular Ca(2+)-mobilizing messenger nicotinic acid adenine dinucleotide phosphate (NAADP) on

69 Nicotinic acid adenine dinucleotide phosphate (NAADP) po

70 In sea urchin eggs, Ca2+ mobilization by nicotinic acid adenine dinucleotide phosphate (NAADP) po

71 The second messenger nicotinic acid adenine dinucleotide phosphate (NAADP) re

72 have shown that cyclic ADPribose (cADPr) and nicotinic acid adenine dinucleotide phosphate (NAADP) re

73 It was reported recently that nicotinic acid adenine dinucleotide phosphate (NAADP) re

74 Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) st

75 ond messengers cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP) st

76 Analogues of nicotinic acid adenine dinucleotide phosphate (NAADP) wi

77 In this study, we compared the effects of nicotinic acid adenine dinucleotide phosphate (NAADP), a

78 Nicotinic acid adenine dinucleotide phosphate (NAADP), a

79 show here that the Ca2+-mobilizing molecule nicotinic acid adenine dinucleotide phosphate (NAADP), a

80 n channels previously thought to be gated by nicotinic acid adenine dinucleotide phosphate (NAADP), a

81 portance of another Ca2+-releasing molecule, nicotinic acid adenine dinucleotide phosphate (NAADP), h

82 The putative intracellular messenger, nicotinic acid adenine dinucleotide phosphate (NAADP), r

83 Nicotinic acid adenine dinucleotide phosphate (NAADP), t

84 s (TPC2) are lysosomal proteins required for nicotinic acid adenine dinucleotide phosphate (NAADP)-ev

85 Nicotinic acid adenine dinucleotide phosphate (NAADP)-ev

86 We have examined the possible role of nicotinic acid adenine dinucleotide phosphate (NAADP)-me

87 isphosphate (InsP(3)), cyclic ADP ribose and nicotinic acid adenine dinucleotide phosphate (NAADP).

88 se Ca2+ from intracellular stores, including nicotinic acid adenine dinucleotide phosphate (NAADP).

89 +) messengers, cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP).

90 m release triggered by the second messenger, nicotinic acid adenine dinucleotide phosphate (NAADP).

91 regulation by inositol 1,4,5-trisphosphate, nicotinic acid adenine dinucleotide phosphate and cyclic

92 ositol trisphosphate, cyclic ADP ribose, and nicotinic acid adenine dinucleotide phosphate with disti

93 , little is known about Ca2+ mobilization by nicotinic acid adenine dinucleotide phosphate, a pyridin

94 e to cyclic adenosine diphosphate ribose and nicotinic acid adenine dinucleotide phosphate, and to th

95 cto-enzymes to produce cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate, and/or ma

96 llular messengers include cyclic ADP ribose, nicotinic acid adenine dinucleotide phosphate, arachidon

97 e-targeted calcium release channels gated by nicotinic acid adenine dinucleotide phosphate, as also a

98 -releasing messengers, cyclic ADP ribose and nicotinic acid adenine dinucleotide phosphate, in initia

99 the ryanodine receptor, or the receptor for nicotinic acid adenine dinucleotide phosphate.

100 +) messengers, cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate.

101 th the nicotinamide group of NADP to produce nicotinic acid adenine dinucleotide phosphate.

102 NAD+ synthetase converts nicotinic acid adenine dinucleotide to NAD+ via an adeny

103 ic NAD+ synthetases use glutamine to amidate nicotinic acid adenine dinucleotide while many purified

104 ases the myocardial levels of 3 metabolites, nicotinic acid adenine dinucleotide, methylnicotinamide,

105 tructurally related nucleotides such as NAD, nicotinic acid adenine dinucleotide, nicotinamide mononu

106 Nicotinic acid adenine dinucleotide-phosphate (NAADP), a

107 t of the potent Ca(2+) mobilizing messenger, nicotinic acid adenine-dinucleotide phosphate (NAADP), a

108 e CD38-derived Ca(2+) mobilizing metabolite, nicotinic acid-adenine dinucleotide phosphate (NAADP), a

109 dition, our results support a novel role for nicotinic acid-adenine dinucleotide phosphate in cannabi

110 ced calcium increase was reduced by blocking nicotinic acid-adenine dinucleotide phosphate- or inosit

111 es in the elucidation of mechanisms by which nicotinic acid affects the lipoprotein profile and, more

112 In addition, we have found that two nicotinic acid aldehydes induce a significant conformati

113 ed reduced cutaneous flushing in response to nicotinic acid, although the improvement in serum free f

114 silencing defect only on medium deficient in nicotinic acid, an NAD(+) precursor.

115 PGD(2) release, whereas isonicotinic acid, a nicotinic acid analog with low affinity for GPR109A, had

116 -ADP-ribose and nicotinamide, a precursor of nicotinic acid and a form of niacin/vitamin B(3).

117 system in which nicotinamide is converted to nicotinic acid and ammonia by nicotinamidase.

118 ve substituted at both the 5-position of the nicotinic acid and at the 8-adenosyl position was also r

119 nadC in B. bronchiseptica was influenced by nicotinic acid and by a NadQ family transcriptional repr

120 positively regulated by the availability of nicotinic acid and glucose.

121 designated AtNIC1, converts nicotinamide to nicotinic acid and has a Km value of 118 +/- 17 microM a

122 tor (GPCR) GPR109a is a molecular target for nicotinic acid and is expressed in adipocytes, spleen, a

123 Immediate-release niacin contains free nicotinic acid and is the least expensive form of over-t

124 ADP by base exchange from exogenous NADP and nicotinic acid and metabolize exogenous NAADP to nicotin

125 Nicotinic acid and nicotinamide were defined as the vita

126 ct and superior pharmacokinetics to those of nicotinic acid and nicotinamide.

127 d that may be a common architecture for both nicotinic acid and quinolinic acid (QA) phosphoribosyltr

128 s of over-the-counter niacin contain no free nicotinic acid and should not be used to treat dyslipide

129 e case in B. pertussis, the known modulators nicotinic acid and sulfate, which silence Bvg-activated

130 that IscS was required for the synthesis of nicotinic acid and the thiazole moiety of thiamine and t

131 ired to explore the 'pleiotropic' effects of nicotinic acid and will ultimately provide a platform fo

132 han 20 mg of daily niacin, which consists of nicotinic acid and/or nicotinamide, there is growing evi

133 eled precursors tryptophan, quinolinic acid, nicotinic acid, and nicotinamide were added to the media

134 riginate from tryptophan (or aspartic acid), nicotinic acid, and nicotinamide, respectively, and conv

135 ic acid; 2-{[3-(trifluoromethyl)phenyl]amino}nicotinic acid], and diclofenac [2-(2-(2,6-dichloropheny

136 related to the consumption of peas (N-methyl nicotinic acid), apples (rhamnitol), and onions (N-acety

137 The therapeutic actions of nicotinic acid are mediated by GPR109A, a Gi protein-cou

138 Endogenous levels of nicotinic acid are too low to significantly impact recep

139 s predominantly use nicotinamide rather than nicotinic acid as a precursor for NAD biosynthesis.

140 L. pneumophila from toxic concentrations of nicotinic acid as judged by analyzing the growth of the

141 Nicotinamide and nicotinic acid as well as nicotinamide riboside (NR) and

142 hese observations explain the characteristic nicotinic acid auxotrophy of Shigella organisms and are

143 The most primitive pathway for nicotinic acid biosynthesis is the reaction of aspartic

144 fects in the activation of genes involved in nicotinic acid biosynthesis, cell wall integrity, and ot

145 of 5a blocked the flushing effect induced by nicotinic acid but not that induced by PGD2.

146 a-2-thiothymine and 80% anthranilic acid/20% nicotinic acid but not with 3-hydroxypicolinic acid.

147 unter sustained-release niacin contains free nicotinic acid, but some brands are hepatotoxic.

148 cost of therapy (at 2000 mg/d) and the free nicotinic acid content (quantified by high-performance l

149 Like nicotinic acid, (D)-beta-OHB inhibits mouse adipocyte li

150 We hypothesize that the nicotinic acid derivative acipimox, an NAD(+) precursor,

151 eptor (PPAR) gamma agonist, pioglitazone and nicotinic acid derivatives may contribute beyond statin

152 -potassium infusion and the potential use of nicotinic acid derivatives, has simplified the method of

153 increased as the N-alkyl chain length of the nicotinic acid derivatizing agent was increased from 1 t

154 improved by a more stable but still reactive nicotinic acid-derived tetrazine and by changing the key

155 inic acid mononucleotide (NaMN) precursor to nicotinic acid dinucleotide (NaAD) followed by its amida

156 nicotinic acid mononucleotide (NaMN) to form nicotinic acid dinucleotide (NaAD).

157 The exact cellular mechanism by which nicotinic acid exerts its antilipolytic effects has not

158 Nicotinic acid, fibrates, statins, and thiazolidinedione

159 4)U, the iscS(-) strain requires thiamin and nicotinic acid for growth in minimal media.

160 Surprisingly, however, omitting nicotinic acid from the growth medium, which reduces cel

161 C1 was completely dependent on the import of nicotinic acid from the growth medium.

162 of the enzyme bound to a substrate analogue, nicotinic acid, from three crystal forms at resolutions

163 Suppression of lipolysis by nicotinic acid gives rise to a prominent rebound and the

164 Nicotinic acid has long been used for the treatment of d

165 in-coupled receptor 109A as the receptor for nicotinic acid has provided insights into how treatment

166 in humans; PUMA-G in mice) as a receptor for nicotinic acid has provided the opportunity to gain grea

167 Our results suggest that the nicotinic acid-HCA2 axis is a novel negative regulator o

168 ing the nonsteroidal anti-inflammatory drugs nicotinic acid (Hnic) and its isomer isonicotinic acid (

169 , while the less potent antitubercular agent nicotinic acid hydrazide produced the corresponding nico

170 dy-state level of radicals was produced from nicotinic acid hydrazide.

171 ulated hLC-Ls released PGD(2) in response to nicotinic acid in a dose-dependant manner (effector conc

172 ls: with (NA+) and without (NA-) infusion of nicotinic acid in nine individuals with poorly controlle

173 novel role of HCA2 (GPR109A) and its ligand nicotinic acid in regulating macrophage function.

174 erved, which was significantly suppressed by nicotinic acid in wild-type BMMs (P<0.04) but not in Hca

175 confirmed the involvement of GPR109A in the nicotinic acid-induced flushing response, a common side

176 and the adaptor proteins, beta-arrestins, in nicotinic acid-induced signaling and physiological respo

177 scriptional profile analysis determined that nicotinic acid induces the expression of a panel of gene

178 In mice, nicotinic acid inhibits lipolysis via PUMA-G, a Gi/o-cou

179 Nicotinic acid is a high affinity ligand, but the endoge

180 Nicotinic acid is an effective treatment for dyslipidemi

181 Nicotinic acid is one of the most effective agents for b

182 thalpy of the OHN LBHB formed in crystalline nicotinic acid is only 7.7+/-0.5 kcal mol(-1) , suggesti

183 Nicotinic acid is required by most isolates of Salmonell

184 Nicotinic acid is the most potent treatment clinically a

185 Nicotinic acid is the only drug that primarily lowers co

186 r NAD(+) precursors, such as nicotinamide or nicotinic acid, is dispensable.

187 P)H were in the same position as that of the nicotinic acid ligand, its C4 atom would be optimally po

188 These results suggest that nicotinic acid mediates its flushing side effect by inte

189 her the 4- or the 5-position position of the nicotinic acid moiety have been synthesized from NADP en

190 The nadD gene, encoding the enzyme nicotinic acid mononucleotide (NaMN) adenylyltransferase

191 HO pathway responds to depletion of cellular nicotinic acid mononucleotide (NaMN) and mediates nicoti

192 syltransferase (NAPRTase; EC 2.4.2.11) forms nicotinic acid mononucleotide (NAMN) and PPi from 5-phos

193 onucleotides nicotinamide mononucleotide and nicotinic acid mononucleotide (NAMN) and thus catalyze N

194 sis, which catalyze the adenylylation of the nicotinic acid mononucleotide (NaMN) precursor to nicoti

195 the transfer of an adenylyl group of ATP to nicotinic acid mononucleotide (NaMN) to form nicotinic a

196 s of the two MtNadD substrates, i.e. ATP and nicotinic acid mononucleotide (NaMN).

197 Bacterial nicotinic acid mononucleotide adenylyltransferase (NaMNA

198 oribosyltransferase (Nampt) and nicotinamide/nicotinic acid mononucleotide adenylyltransferase (Nmnat

199 Increased levels of nicotinamide/nicotinic acid mononucleotide adenylyltransferase (NMNAT

200 y either route 2 or route 3 is deamidated to nicotinic acid mononucleotide and converted to NAD by th

201 more, two novel deamidation steps leading to nicotinic acid mononucleotide and nicotinic acid ribosid

202 A nicotinic acid mononucleotide derivative is tethered to

203 e the substrates of these enzymes, including nicotinic acid mononucleotide, nicotinamide mononucleoti

204 osynthesis, that all anabolism flows through nicotinic acid mononucleotide, was challenged experiment

205 6 gene, a homolog of E. coli gene nadD, is a nicotinic acid mononucleotide-preferring adenylyltransfe

206 nicotinamide, respectively, and converge on nicotinic acid mononucleotide.

207 ted by lowering basal plasma FFA levels with nicotinic acid (NA) (100-150 mg p.o., q 30 min x 4 h) in

208 ased slowly; 2) during 4 h (from 16-20 h) of nicotinic acid (NA) administration (fasting plus NA), wh

209 tinate mononucleotide and pyrophosphate from nicotinic acid (NA) and phosphoribosyl pyrophosphate (PR

210 which followed lowering of plasma FFAs with nicotinic acid (NA) and was a consequence of increased l

211 asma FFA were lowered at 16 to 20 hours with nicotinic acid (NA) and were then allowed to rise at 20

212 A level in intact fasted rats by infusion of nicotinic acid (NA) caused essentially complete ablation

213 1778-induced ROS can be diminished by adding nicotinic acid (NA) in a NA phosphoribosyltransferase 1

214 Nicotinic acid (NA) is commonly used to treat dyslipidem

215 hey received an infusion of either saline or nicotinic acid (NA) to deplete their plasma FFA pool, fo

216 hat the inducing signal is the limitation of nicotinic acid (NA), a precursor of nicotinamide adenine

217 Here we report that nicotinic acid (NA), an essential vitamin, inhibits glio

218 wo enzymes that sequentially convert NAD+ to nicotinic acid (NA), are up-regulated during CR.

219 ty toward the normally inactive QA analogue, nicotinic acid (NA), indicating roles for these residues

220 (+) to be synthesized from three compounds - nicotinic acid (NA), nicotinamide (NAM) and nicotinamide

221 iae, the nicotinamidase Pnc1 converts NAM to nicotinic acid (NA), which is then used as a substrate b

222 changing the nicotinamide group of NADP with nicotinic acid (NA).

223 5-phosphoribosyl 1-pyrophosphate (PRPP) and nicotinic acid (NA).

224 Nicotinic acid (NA, a.k.a. vitamin B3 or niacin) can red

225 During period 2, saline (nicotinic acid [NA], n = 7), lipid emulsion (NA plus lip

226 We report here that nicotinic acid (NAc) and its metabolic precursor, quinol

227 thyl-5,6,7,8-tetrahydronaphthalen-2-yl)amino)nicotinic acid (NEt-TMN) were synthesized and assessed f

228 3'-dideoxyadenosine (DDA), MDL-12330A (MDL), nicotinic acid (NIC-A)).

229 nt was with the adenylate cyclase inhibitors nicotinic acid (NIC-A), 2',3'-dideoxyadenosine (DDA), or

230 (CYS); (ii) the adenylate cyclase inhibitors nicotinic acid (NIC-A), 2',3'dideoxyadenosine (DDA), or

231 m multiple precursors, including tryptophan, nicotinic acid, nicotinamide, and nicotinamide riboside

232 etic and/or ligand activities of tryptophan, nicotinic acid, nicotinamide, and the newly identified N

233 Attachment of charged groups to the nicotinic acid of NAADP is associated with loss of activ

234 o be the molecular target for the actions of nicotinic acid on adipose tissue, and in this issue of t

235 icotinamide riboside uptake without altering nicotinic acid or nicotinamide import.

236 Nicotinic acid, or its analogues, seems to alleviate ins

237 tes with the NAD(+) precursors nicotinamide, nicotinic acid, or nicotinamide mononucleotide, the Ca(2

238 alvage" pathways starting from nicotinamide, nicotinic acid, or nicotinamide riboside (NR).

239 e dinucleotide, nicotinamide mononucleotide, nicotinic acid, or nicotinamide.

240 The broad utility of the nicotinic acid pathway to couple central metabolism and

241 o-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243), a known hERG channel activat

242 o-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid [PD307243 (PD)] and 1,3-bis-(2-hydroxy-5-

243 for dyslipidemia, oral doses of 1-3 grams of nicotinic acid per day lower serum triglycerides, raise

244 , flufuran, gregatin B, hydroxysydonic acid, nicotinic acid, phomaligin A, spinulosin and terrein.

245 nicotinamide phosphoribosyl transferase and nicotinic acid phosphoribosyl transferase showed moderat

246 Here, we show the gene encoding nicotinic acid phosphoribosyltransferase (NAPRT), a seco

247 Nicotinic acid phosphoribosyltransferase (NAPRTase; EC 2

248 Nicotinic acid phosphoribosyltransferase (NAPRTase; EC 2

249 udomonas, which is encoded on an operon with nicotinic acid phosphoribosyltransferase and, in some Ps

250 Two putative nicotinic acid phosphoribosyltransferases, PncB1 (Rv1330

251 In addition to hydrolyzing nicotinamide into nicotinic acid, PncA also hydrolyzes the prodrug pyrazin

252 In addition, we found that nicotinic acid promoted the binding of beta-arrestin1 to

253 esirable and undesirable clinical actions of nicotinic acid raises interesting questions regarding th

254 Nicotinic acid receptor (GPR109A) gene expression was as

255 ery and characterization of a membrane-bound nicotinic acid receptor (HM74) explains niacin's acute i

256 The human ortholog HM74a is also a nicotinic acid receptor and likely has a similar role in

257 targeting the beta-adrenergic receptors and nicotinic acid receptor GPR109a highlight the powerful c

258 Research on signalling through the nicotinic acid receptor might give rise to novel and mor

259 Treatment with nicotinic acid reduced nuclear factor kappaB (NF-kappaB)

260 Nicotinic acid remains the most effective therapeutic ag

261 Treatment with 300 muM nicotinic acid (reported EC50 3 muM, peak plasma concent

262 es pncA and pncB, for use of nicotinamide or nicotinic acid, respectively, for NAD synthesis.

263 Substitution at the 4-position of the nicotinic acid resulted in the loss of agonist potency f

264 id as well as nicotinamide riboside (NR) and nicotinic acid riboside (NAR) are the major precursors f

265 Here, we show that nicotinamide riboside and nicotinic acid riboside are authentic intracellular meta

266 we discovered that nicotinamide riboside and nicotinic acid riboside are biosynthetic precursors of N

267 se and nicotinamide riboside kinase and that nicotinic acid riboside bioavailability is increased by

268 for production of nicotinamide riboside and nicotinic acid riboside in cells.

269 leading to nicotinic acid mononucleotide and nicotinic acid riboside production are also uncovered th

270 Finally, we show that yeast nicotinic acid riboside utilization largely depends on u

271 tracellular levels of nicotinamide riboside, nicotinic acid riboside, and other NAD(+) metabolites we

272 Nicotinamide riboside, nicotinic acid riboside, O-ethylnicotinate riboside, O-m

273 alian purine nucleoside phosphorylase cleave nicotinic acid riboside, whereas the yeast phosphorylase

274 e yeast phosphorylase has little activity on nicotinic acid riboside.

275 nd potent agonist and allosteric enhancer of nicotinic acid's action, was the basis for most other co

276 This defect prevents nicotinic acid secretion, which is the basis for the nia

277 Nicotinic acid significantly inhibited wild-type BMM che

278 For 1b, "inactive" pyridine and nicotinic acid speed up the demetalation in the presence

279 The nicotinic acid stacks between the re face of the FMN and

280 and colleagues proposed a mechanism in which nicotinic acid stimulates cholesterol mobilisation from

281 As nicotinic acid stimulates the GPCR GPR109A and Gi/Go pro

282 In a human cell line-based signaling assay, nicotinic acid stimulation led to pertussis toxin-sensit

283 nlipid-mediated anti-inflammatory effects of nicotinic acid such as direct enhancement of adiponectin

284 icative L. pneumophila are treated with 5 mM nicotinic acid, the bacteria induce numerous transmissiv

285 g response but can antagonize the ability of nicotinic acid to elicit a flush response in vivo.

286 e benefits likely result from the ability of nicotinic acid to inhibit lipolysis in adipocytes and th

287 ed function, the gene most highly induced by nicotinic acid treatment encodes a putative major facili

288 oreover, an additional 213 genes specific to nicotinic acid treatment were altered.

289 Whether nicotinic acid use becomes routine in the treatment of a

290 Nicotinic acid, used for atherosclerosis treatment, has

291 cted mutants bound to the substrate analogue nicotinic acid, using X-ray crystallography.

292 onjugated with neuroactive carriers, namely, nicotinic acid, valproic acid, theophylline-7-acetic aci

293 The average content of free nicotinic acid was 520.4 mg for immediate-release niacin

294 id, whereas under anaerobic conditions, only nicotinic acid was required.

295 Both N6-phenylisopropyl adenosine and nicotinic acid were less potent and efficacious inhibito

296 f IscS caused an auxotrophy for thiamine and nicotinic acid, whereas under anaerobic conditions, only

297 ketosulfoxides, isosteres of pyrazinoic and nicotinic acids, which should inhibit mycobacterial grow

298 Yeast cells convert nicotinamide to nicotinic acid, while mammals lack the enzyme nicotinami

299 Interactions of the nicotinic acid with backbone atoms indicate the structur

300 to produce cyclic ADP-ribose and exchanging nicotinic acid with the nicotinamide group of NADP to pr